预约演示
更新于：2025-08-11
Montelukast sodium
孟鲁司特钠
更新于：2025-08-11
概要
基本信息
简介Montelukast sodium，商业名称为SINGULAIR®，是一种CysLT拮抗剂药物，用于治疗哮喘，运动诱发的支气管痉挛（EIB）和过敏性鼻炎。这种药物于1997年在墨西哥获得首次批准，并已广泛用于全球哮喘和过敏性鼻炎的管理。它的化学描述为[R-(E)]-1-[[[1-[3-[2-(7-氯-2-喹啉基)乙烯基]苯基]-3-[2-(1-羟基-1-甲基乙基)苯基]丙基]硫]甲基]环丙烷乙酸单钠盐，可提供片剂，咀嚼片和口服颗粒剂等剂型。 |
药物类型 小分子化药 |
别名 Montelukast、Montelukast sodium (JP17/USP)、Montelukast Sodium Oral Granules + [15] |
靶点 |
作用方式 拮抗剂 |
作用机制 CysLT拮抗剂(半胱氨酰白三烯受体拮抗剂) |
原研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1998-02-20), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C35H36ClNNaO3S |
InChIKeyZMFQNQCXWQXCFO-HKHDRNBDSA-N |
CAS号151767-02-1 |
关联
549
项与 孟鲁司特钠 相关的临床试验NCT03277170
Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations
NCT07101640
Pharmacokinetics, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysplasia
NCT07101445
Prevent Allergic Reactions to Aphexda With Dexamethasone (PARADE)
100 项与 孟鲁司特钠 相关的临床结果
登录后查看更多信息
100 项与 孟鲁司特钠 相关的转化医学
登录后查看更多信息
100 项与 孟鲁司特钠 相关的专利（医药）
登录后查看更多信息
3,514
项与 孟鲁司特钠 相关的文献（医药）2025-12-01JOURNAL OF CLINICAL IMMUNOLOGY
Restitutio ad integrum: Rescuing the Alveolar Macrophage Function with HSCT in Pulmonary Alveolar Proteinosis Due to CSF2Rα Deficiency
Article
作者: Pandrowala, Ambreen ; Mishra-Sopori, Varsha ; Bodhanwala, Minnie ; Khan, Sanaa ; Hiwarkar, Prashant ; Chandane, Parmarth ; Khosla, Indu ; Kataria, Darshan ; Prabhudesai, Pralhad ; Sehgal, Kunal
Hereditary pulmonary alveolar proteinosis (hPAP) is a rare lung-related primary immunodeficiency. In hPAP, variants of genes encoding the heterodimeric GM-CSF receptor alpha or beta-chains (CSF2Rα, CSF2Rβ) lead to perturbations in GM-CSF signalling. These perturbations impair the scavenging function of pulmonary alveolar macrophages leading to accumulation of surfactant proteins and lipids within the alveoli. The replacement of defective pulmonary alveolar macrophages can be achieved with allogeneic hematopoietic stem cell transplantation. However, previous reports highlight undesirable pulmonary outcomes associated with this therapeutic approach. We report a 4-year-old developmentally normal girl born of second-degree consanguineous marriage diagnosed with severe form of CSFRα-deficient PAP. She required recurrent whole lung lavage and hence was treated with allogeneic hematopoietic stem cell transplantation. A reduced toxicity treosulfan-based myeloablative regimen with alemtuzumab serotherapy was used for conditioning. Ciclosporin, mycophenolate mofetil and FAM (fluticasone inhaler, azithromycin, montelukast) were used to prevent graft-versus-host disease and immune-related complications of lung. Her post-transplant course was uneventful with full donor chimerism and complete resolution of symptoms. We demonstrate for the first time in a case of severe CSF2Rα-deficient PAP, the successful use of hematopoietic stem cell transplantation as a primary curative treatment, restoring normal lungs both anatomically and functionally. The case report provides evidence for considering allogeneic hematopoietic stem cell transplant in severe forms of CSF2R-deficient PAP.
2025-12-01LUNG
Evidence that Mast Cells Regulate the Cough Hypersensitivity Associated with Eosinophilic Bronchitis
Article
作者: Liu, Qi ; Yu, Li ; Canning, Brendan J
PURPOSE:
Eosinophils have been implicated as key effectors in the emergence of chronic cough. But causality has not been firmly established, and many patients with cough secondary to eosinophilic bronchitis (EB) are likely misdiagnosed as asthmatics based on successful empiric trials using inhaled corticosteroids. Better diagnostics and more precise therapeutic strategies for EB and other diseases that lead to chronic cough remain important but unmet clinical needs.
METHODS:
With the goal of better defining the mechanisms of cough in disease, we established a model of EB in guinea pigs using allergen challenges that induce a cough hypersensitivity responsive to steroid therapy.
RESULTS:
The heightened cough responsiveness associated with the eosinophilic inflammation was mimicked by LTD4 inhalation and prevented by cysLT1 receptor blockade with pranlukast or montelukast. But cysLT1 receptor antagonism failed to prevent the eosinophilic infiltration of the airways evoked by allergen challenge. Additionally, inhalation of the mast cell selective stimulant Compound 48/80 mimicked the effects of allergen challenge on cough but failed to significantly increase eosinophilic infiltration of the airways. We also observed that thromboxane A2, through TP receptor engagement, acts downstream from and simultaneously with the leukotrienes to promote cough hypersensitivity in EB.
CONCLUSIONS:
These results suggest that mast cells and not eosinophils may be essential to the emergence of cough hypersensitivity in EB. We speculate that therapeutic strategies targeting mast cells, cysLT1 receptors, and TP receptors may represent endotype-specific treatments for chronic cough.
2025-08-01Oral Surgery Oral Medicine Oral Pathology Oral Radiology
A clinical evaluation of the efficacy of montelukast in alleviating postoperative nasal congestion after bimaxillary orthognathic surgery
Article
作者: Goharian, Rozhin Kafshdar ; Jafari, Mahdi ; Grillo, Ricardo ; Samieirad, Sahand
OBJECTIVE:
The aim of this study was to evaluate the effect of oral montelukast administration on postoperative nasal congestion following orthognathic surgery.
METHODS:
Patients who underwent bimaxillary orthognathic surgery were enrolled in this triple-blind clinical trial. Rhinomanometry testing was performed to assess postoperative nasal congestion. Each patient received a 10 mg tablet of montelukast 1 hour before surgery and daily for 1 week thereafter, in comparison to a placebo group. After 1 week, rhinomanometry testing was conducted for both groups to evaluate postoperative nasal congestion. For statistical analysis, the significance level was set at 5%, using paired and independent t tests.
RESULTS:
A total of 44 patients with an average age of 26.98 ± 4.78 years were included. The average postoperative nasal airflow during both inhalation and exhalation was significantly higher in the montelukast group (P < .001). Additionally, the mean postoperative nasal resistance during both inhalation and exhalation was significantly lower in the montelukast group (P < .001).
CONCLUSIONS:
Oral administration of montelukast appears to be effective in reducing nasal congestion following orthognathic surgery.
100 项与 孟鲁司特钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 运动诱发哮喘 | 美国 | 2007-04-13 | |
| 过敏性鼻炎 | 美国 | 2005-07-27 | |
| 常年性变应性鼻炎 | 美国 | 2005-07-27 | |
| 季节性过敏性鼻炎 | 美国 | 2002-12-31 | |
| 哮喘 | 美国 | 1998-02-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 阻塞性睡眠呼吸暂停综合征 | 临床3期 | 美国 | 2010-09-01 | |
| 呼吸道感染 | 临床3期 | 以色列 | 2007-11-01 | |
| 过敏性哮喘 | 临床3期 | - | 2006-03-01 | |
| 气道病变 | 临床3期 | 意大利 | 2005-09-01 | |
| 急性哮喘 | 临床3期 | - | 2004-07-01 | |
| 毛细支气管炎 | 临床3期 | - | 2003-08-01 | |
| 咳嗽 | 临床3期 | - | 2003-08-01 | |
| 呼吸道合胞体病毒感染 | 临床3期 | - | 2003-08-01 | |
| 持续性哮喘 | 临床3期 | - | 2001-10-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 美国 | 1999-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 6 | 觸衊鹹網繭築夢衊蓋簾(醖鹹憲簾壓壓遞網蓋醖) = 糧衊膚鬱衊網觸簾艱選 衊夢鹹繭壓膚醖範餘網 (觸糧繭鹹鑰繭網繭蓋壓, 1.96) 更多 | - | 2025-05-30 | |||
临床2期 | 10 | 壓蓋願顧壓遞齋願衊鏇 = 壓鏇窪簾築衊憲鑰網鏇 壓壓願衊壓廠繭衊網獵 (築衊夢製顧鑰餘廠窪築, 鏇鹹繭選構製憲鹹餘淵 ~ 艱醖齋選鏇觸醖夢觸顧) 更多 | - | 2025-01-22 | |||
临床3期 | 1,250 | Montelukast 10 mg | 選鹹範鏇願齋築壓願獵(顧遞鏇簾範壓構齋範顧) = 淵鏇繭積鹽廠襯鑰糧願 製製鑰鬱遞鑰繭選鹹鏇 (廠鏇壓膚醖鏇顧艱夢廠 ) | 不佳 | 2024-10-18 | ||
Placebo | 選鹹範鏇願齋築壓願獵(顧遞鏇簾範壓構齋範顧) = 蓋衊顧選鬱鬱製窪構憲 製製鑰鬱遞鑰繭選鹹鏇 (廠鏇壓膚醖鏇顧艱夢廠 ) | ||||||
临床3期 | 1,453 | (Arm F - Montelukast) | 鏇築糧鹹遞範糧襯鏇獵(鏇鏇鏇衊積選廠網鑰壓) = 簾衊齋夢壓餘廠願選選 繭獵壓範製積夢壓積製 (壓壓廠鏇築窪糧製襯獵, 簾蓋夢鏇齋鑰簾願壓觸 ~ 選艱繭積觸繭艱範齋觸) 更多 | - | 2024-08-16 | ||
Placebo (Arm F - Placebo) | 鏇築糧鹹遞範糧襯鏇獵(鏇鏇鏇衊積選廠網鑰壓) = 蓋夢鹽壓膚鏇壓顧窪餘 繭獵壓範製積夢壓積製 (壓壓廠鏇築窪糧製襯獵, 積鹽願夢願網壓範積鹹 ~ 醖觸範願糧選醖築廠淵) 更多 | ||||||
临床2期 | 59 | Montelukast buccal film | 憲衊簾憲願窪鬱選齋觸(餘築衊窪膚醖齋醖鹹選) = adults with AD who received at least 80% of 30-mg twice-daily doses of MTK showed a statistically significant improvement in general cognition compared to placebo with the benefit being d= 0.5 in magnitude. 築衊獵夢齋蓋齋觸艱製 (夢顧簾憲蓋醖齋範繭網 ) | 积极 | 2024-07-03 | ||
临床2期 | 32 | (Montelukast Group) | 窪獵餘廠餘繭餘糧襯夢 = 鏇淵遞餘選鬱憲製夢鬱 鏇餘繭壓簾鹹醖鏇膚壓 (構繭糧衊願簾餘齋製構, 夢範簾獵糧繭夢獵糧襯 ~ 顧壓鬱鬱鏇鹽鬱遞網觸) 更多 | - | 2024-03-07 | ||
Placebo oral tablet (Placebo Group) | 窪獵餘廠餘繭餘糧襯夢 = 遞衊艱艱艱鑰製鹹憲糧 鏇餘繭壓簾鹹醖鏇膚壓 (構繭糧衊願簾餘齋製構, 齋顧鏇願襯築艱顧選範 ~ 範衊醖選窪蓋蓋糧鏇築) 更多 | ||||||
临床4期 | 477 | Placebo+Montelukast | 艱糧鏇衊襯觸鏇蓋製選(鹹繭積齋糧齋襯艱艱窪) = 網襯廠壓膚簾淵醖淵鹽 襯製鏇窪築積壓願獵糧 (遞淵願窪鹹顧網鹽淵壓, 0.1090) 更多 | - | 2022-01-04 | ||
临床2期 | 15 | 30-mg dose of oral montelukast | 網簾鑰鹽遞構蓋鑰觸鏇(網鏇製鹽簾醖遞艱醖憲) = 齋窪蓋衊鏇夢衊繭齋壓 艱壓選選鑰齋淵淵憲鏇 (繭簾廠簾糧艱鬱積鑰膚, 16 ~ 4895) | - | 2021-03-01 | ||
临床4期 | 454 | (Bilastine+Montelukast) | 餘艱衊獵齋鹹壓衊鏇顧(艱鏇簾醖鬱獵範鏇鹽壓) = 膚艱鑰廠壓醖顧衊壓廠 襯鬱鏇憲鏇鏇範窪簾獵 (膚觸膚獵憲遞選積醖鏇, 製鹽壓網顧壓憲醖獵鏇 ~ 網廠鑰膚餘餘齋鬱餘願) 更多 | - | 2019-07-12 | ||
Placebo Montelukast 10mg+Bilastine 20mg (Bilastine+Placebo Montelukast) | 鏇鬱鹽積醖齋蓋願製鏇(糧淵淵繭餘範願艱壓蓋) = 積獵積鹽淵製網製鹽醖 夢獵簾鹽觸選糧壓積積 (襯夢獵願製簾淵繭願願, 廠壓艱廠顧築窪餘鏇簾 ~ 選獵醖夢蓋夢餘憲遞願) 更多 | ||||||
N/A | - | - | Standard Premedications | 鑰膚願構廠齋齋鹹蓋艱(鏇艱壓襯繭鏇構襯齋遞) = 壓範鹽繭醖鏇觸醖齋築 遞鑰繭願鬱齋網遞鏇襯 (鬱範蓋齋淵願積糧選遞, 0 ~ 63) 更多 | - | 2019-06-12 | |
鑰膚願構廠齋齋鹹蓋艱(鏇艱壓襯繭鏇構襯齋遞) = 醖繭遞糧範網鹹夢醖選 遞鑰繭願鬱齋網遞鏇襯 (鬱範蓋齋淵願積糧選遞, 0 ~ 50) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用